Bronchial Biopsy Devices Market By Product Type (Flexible Bronchoscopes, Needle-Based Biopsy Devices, Forceps); By Application (Lung Cancer Diagnosis, Chronic Obstructive Pulmonary Disease [COPD] Diagnosis, Asthma and Other Respiratory Conditions); By End User (Hospitals, Diagnostic Clinics, Research Institutions, Contract Research Organizations); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

Rising Lung Cancer Diagnostics and Advanced Bronchoscopy Technologies Strengthen Bronchial Biopsy Devices Market Growth

The Global Bronchial Biopsy Devices Market was valued at USD 1.1 billion in 2025 and is expected to reach USD 1.8 billion by 2032, growing at a CAGR of 6.4%.

 

Bronchial biopsy devices are central to minimally invasive pulmonary diagnosis, allowing clinicians to obtain tissue samples from the airways, lung lesions, and regional lymph nodes during bronchoscopy. These specimens support the diagnosis and characterization of lung cancer, persistent respiratory infections, inflammatory lung disorders, and abnormalities detected on chest imaging, often reducing the need for more invasive surgical biopsy procedures.

 

Lung cancer diagnosis and staging represent major clinical applications. Bronchial tissue sampling helps confirm malignancy, characterize tumors, and assess mediastinal or hilar lymph node involvement for treatment planning. The broader oncology burden continues to support demand for diagnostic procedures, with approximately 2.11 million new cancer cases diagnosed annually in the United States and nearly 21 million new cases reported globally. Cancer patients may undergo multiple investigations, including imaging, tissue biopsy, molecular testing, and laboratory assessment, before treatment decisions are finalized.

 

Bronchial biopsy devices also play an important role beyond oncology. Bronchoscopic tissue sampling is used to investigate persistent bacterial, fungal, or viral infections and evaluate inflammatory pulmonary diseases such as sarcoidosis and selected interstitial lung disorders. More than 15 million Americans live with diagnosed autoimmune or chronic inflammatory conditions, although only a proportion develop pulmonary involvement requiring bronchoscopic evaluation. This broader inflammatory disease burden contributes to demand for specialized diagnostic testing when respiratory involvement is suspected.

 

A substantial bronchoscopy procedure base creates recurring demand for biopsy instruments and related consumables. Approximately 500,000 bronchoscopies are performed annually in the United States across hospitals, intensive care units, and outpatient diagnostic centers. Based on North America's estimated 36% to 41% share of global bronchoscopy activity, worldwide procedure volume can be approximated at 1.2 million to 1.4 million procedures annually. Diagnostic applications account for roughly 68% to 70% of bronchoscopy procedures, reflecting significant use for tissue biopsy, endobronchial ultrasound, and related diagnostic evaluations.

 

Several device technologies address different tissue-sampling requirements. Conventional biopsy forceps are commonly used to remove tissue from visible or centrally located airway lesions. Transbronchial needle aspiration and EBUS-guided needles allow clinicians to sample deeper pulmonary lesions and mediastinal or hilar lymph nodes, supporting both diagnosis and disease staging.

 

Cryobiopsy technology is expanding the ability to obtain larger and better-preserved specimens. Cryoprobes rapidly freeze targeted tissue, allowing samples to be removed while maintaining tissue architecture for histopathological and molecular evaluation. Obtaining sufficient, high-quality tissue has become increasingly important as lung cancer treatment decisions rely on tumor subtyping, genomic profiling, and biomarker analysis for targeted therapies and immunotherapies.

 

Navigation-assisted and robotic bronchoscopy platforms are further advancing peripheral lung biopsy by improving access to small and difficult-to-reach pulmonary nodules. Steerable catheters, real-time imaging, electromagnetic or computer-assisted navigation, and robotic control allow biopsy instruments to reach deeper regions of the bronchial tree. These capabilities are becoming increasingly relevant as CT imaging and lung cancer screening programs detect greater numbers of small pulmonary lesions requiring tissue confirmation.

 

FDA-cleared bronchial and lung biopsy technologies are increasingly centered on robotic navigation systems, advanced biopsy needles, and image-guided targeting tools. Major platforms such as Intuitive's Ion and Johnson & Johnson's Monarch use highly steerable catheters to navigate toward small peripheral lung nodules. Automated and core biopsy technologies, including systems such as EndoCore, are designed to improve tissue yield and support the growing need for molecular and genetic analysis. Three-dimensional cone-beam CT guidance and other advanced imaging technologies can further improve lesion localization and procedural accuracy, while lung-sealing and safety technologies are being developed to reduce complications associated with pulmonary biopsy.

 

The technology pipeline is moving toward greater automation, procedural intelligence, and real-time assessment. AI-enabled software is being explored to support navigation, lesion targeting, and immediate evaluation of biopsy sample adequacy, potentially helping clinicians determine whether sufficient diagnostic tissue has been collected before completing the procedure. Continued integration of robotics, advanced imaging, precision biopsy instruments, and digital decision-support technologies is expected to strengthen the effectiveness of minimally invasive lung tissue sampling.

 

North America remains a major market for bronchial biopsy technologies because of its high bronchoscopy volumes, established pulmonary care infrastructure, widespread lung cancer screening, and significant burden of lung cancer and chronic respiratory disease. Europe and Asia-Pacific also represent substantial procedural markets, supported by growing respiratory disease prevalence, expanding hospital infrastructure, and increasing availability of advanced bronchoscopy technologies.

 

Overall, the bronchial biopsy devices market is progressing from conventional forceps and aspiration needles toward cryobiopsy, EBUS-guided sampling, robotic navigation, advanced imaging, and automated tissue-acquisition technologies. Rising lung cancer diagnostic requirements, increasing detection of pulmonary nodules, a large recurring bronchoscopy procedure base, growing demand for high-quality specimens for molecular analysis, and continued adoption of minimally invasive diagnostic technologies are strengthening the market across pulmonology, thoracic oncology, and interventional bronchoscopy.

 

How Are Product Types Shaping the Bronchial Biopsy Devices Market?

Flexible Bronchoscopes

Flexible bronchoscopes accounted for an estimated 44% market share in 2025, representing approximately USD 484 million, and the segment is projected to expand at a CAGR of 6.2% through 2032. Flexible bronchoscopes remain the largest product segment because they provide the access route through which physicians visualize airways and introduce biopsy instruments. Demand is increasingly supported by efforts to reach smaller and more peripheral lesions. For example, Olympus' BF-MP190F is compatible with radial EBUS probes and multiple sampling devices for accessing distal airways, while the company's broader portfolio includes reusable and single-use flexible bronchoscopes. Greater biopsy activity therefore generates demand for both the bronchoscopy platform and the instruments passed through it.

 

Needle-Based Biopsy Devices

Needle-based biopsy devices held an estimated 36% share in 2025, equal to approximately USD 396 million, and are expected to record the fastest product CAGR of 7.8% through 2032. Growth is being driven by EBUS-guided lymph-node sampling, peripheral pulmonary nodule investigation, lung-cancer staging, and increasing demand for tissue suitable for histopathology and molecular testing. For example, Boston Scientific's Acquire Pulmonary device is designed for EBUS-guided fine-needle biopsy of tracheobronchial lesions, while Medtronic offers pulmonary aspirating and biopsy needles for endobronchial lesions, peripheral nodules, and lung masses. Improved peripheral navigation is widening the number of lesions that can be reached bronchoscopically, creating additional procedure-linked needle consumption.

 

Forceps

Forceps represented an estimated 20% of the market in 2025, generating approximately USD 220 million, and are forecast to grow at a CAGR of 5.5% through 2032. Forceps remain widely used for collecting tissue from visible endobronchial lesions and selected peripheral abnormalities, but their growth is more moderate as needle-based and cryobiopsy approaches gain importance in complex sampling. For example, Medtronic's superDimension biopsy forceps are intended for histological tissue collection, while Olympus bronchoscope platforms support forceps alongside needles, brushes, and radial EBUS instruments. Continued bronchoscopy volumes maintain recurring forceps demand even as hospitals diversify their biopsy-tool mix.

 

Which Applications Generate the Largest Bronchial Biopsy Device Demand?

Lung Cancer Diagnosis

Lung cancer diagnosis accounted for an estimated 66% market share in 2025, representing approximately USD 726 million, and is projected to grow at a CAGR of 7.0% through 2032. It is the dominant application because tissue is frequently required to confirm malignancy, establish histology, stage disease, and support biomarker-driven treatment decisions. GLOBOCAN 2024 estimates approximately 2.64 million new lung, bronchus, and trachea cancers worldwide, while the supplied U.S. analysis identified 228,058 newly reported lung cancers in 2023.
Demand is also being supported by earlier detection. Medicare covers annual LDCT screening for eligible beneficiaries aged 50–77 with the required smoking history, while the American College of Radiology expanded its registry in October 2025 to include actionable incidental pulmonary nodules identified outside formal screening. More suspicious nodules entering organized follow-up can increase the number of patients progressing to bronchoscopy and biopsy when tissue confirmation is required.

 

Chronic Obstructive Pulmonary Disease (COPD) Diagnosis

COPD diagnosis represented an estimated 11% market share in 2025, equivalent to approximately USD 121 million, and is forecast to increase at a CAGR of 4.8% through 2032. Bronchial biopsy is not the routine primary diagnostic pathway for COPD; GOLD and the Global Lung Function Initiative continue to identify spirometry as central to confirming airflow obstruction. Device demand within this segment therefore comes mainly from patients undergoing bronchoscopy because of unresolved airway abnormalities, suspected malignancy, overlapping pulmonary disease, or research evaluation. For example, Johnson & Johnson's TARGET study of robotic bronchoscopy included patients with COPD or emphysema while evaluating access and biopsy of pulmonary nodules, illustrating how COPD patients can enter biopsy pathways when suspicious lesions coexist.

 

Asthma and Other Respiratory Conditions

Asthma and other respiratory conditions accounted for an estimated 23% share in 2025, representing approximately USD 253 million, and are expected to grow at a CAGR of 5.9% through 2032. Most commercial demand within this broad category comes from other respiratory conditions—including interstitial lung disease, sarcoidosis, mediastinal abnormalities, and selected post-transplant investigations—rather than routine asthma diagnosis. GINA's current diagnostic strategy for asthma centers on clinical assessment and objective lung-function or inflammatory-marker evidence rather than routine bronchial biopsy.

The supplied research estimated approximately 4.58 million prevalent ILD/pulmonary-sarcoidosis cases and 428,160 incident cases globally in 2023. For example, ERBE provides flexible single-use cryoprobes for transbronchial and peripheral pulmonary biopsy, while Boston Scientific's pulmonary FNB portfolio includes applications such as suspected sarcoidosis.

 

Which End Users Control Bronchial Biopsy Device Purchasing?

Hospitals

Hospitals held the largest estimated end-user share of 60% in 2025, representing approximately USD 660 million, and are projected to grow at a CAGR of 6.6% through 2032. Hospitals concentrate interventional pulmonology, EBUS, lung-cancer staging, robotic bronchoscopy, pathology, anesthesia, and emergency support needed for complex biopsy procedures. The supplied CMS analysis identified 135,559 selected bronchoscopic biopsy and EBUS code-line services in 2024 Original Medicare fee-for-service alone, demonstrating substantial procedure-based utilization. Hospital investment in platforms such as Intuitive's Ion and Johnson & Johnson's MONARCH can also increase downstream consumption of biopsy tools as access to peripheral lesions improves.

 

Diagnostic Clinics

Diagnostic clinics accounted for an estimated 20% market share in 2025, equal to approximately USD 220 million, and are forecast to grow at a CAGR of 6.2% through 2032. Growth reflects expansion of specialist pulmonary centers, ambulatory diagnostic services, nodule-management programs, and outpatient bronchoscopy. ACR's expansion of early lung-cancer detection tracking to incidental pulmonary nodules can encourage more structured follow-up across diagnostic networks. As outpatient diagnostic infrastructure increases, clinics capable of bronchoscopy can capture procedures that otherwise occur in hospital departments.

 

Research Institutions

Research institutions represented an estimated 12% share in 2025, generating approximately USD 132 million, and are projected to expand at a CAGR of 5.5% through 2032. Universities and academic medical centers use bronchial biopsy devices in pulmonary disease research, biomarker studies, translational oncology, and evaluation of new sampling approaches. Demand is smaller than routine clinical purchasing but remains important for newer methods such as robotic biopsy and cryobiopsy. For example, the multicenter TARGET program evaluated robotic-assisted bronchoscopy across 21 sites, while pulmonary cryobiopsy continues to be studied for peripheral and interstitial lung lesions.

 

Contract Research Organizations

Contract research organizations accounted for an estimated 8% share in 2025, equivalent to approximately USD 88 million, and are forecast to record a CAGR of 7.4% through 2032. CRO demand is linked to device trials, diagnostic studies, pulmonary drug-development programs, and multicenter investigations requiring standardized respiratory tissue collection. As precision-oncology and biomarker programs require better-quality lung tissue, CROs coordinating multi-site research can generate additional demand for standardized biopsy products and procedure support.

 

Why Is Bronchoscopic Procedure Volume Becoming More Commercially Important?

Direct procedure utilization provides a stronger demand signal than simply counting patients with respiratory disease. In 2024, Original Medicare FFS recorded 12,438 endobronchial biopsy services, 43,256 transbronchial lung biopsy services, 31,043 transbronchial needle aspiration/biopsy services, 27,889 EBUS sampling services involving one to two stations, and 20,933 involving three or more stations. The selected codes total 135,559 code-line services.

Peripheral access is also increasing the commercial opportunity. Johnson & Johnson reported that the MONARCH platform reached targeted small and peripheral lung nodules in 98.7% of patients in the TARGET study, which followed 679 patients across 21 sites. Intuitive's latest Ion software adds AI-supported navigation and advanced imaging capabilities intended to improve access to small, difficult-to-reach nodules during lung biopsy. These systems sit adjacent to the biopsy-device market but can increase demand for needles and forceps by bringing more lesions within bronchoscopic reach.

 

Which Regions Offer the Strongest Growth Opportunities?

North America

North America accounted for an estimated 39% share of the Bronchial Biopsy Devices Market in 2025, representing approximately USD 429 million, and is forecast to grow at a CAGR of 6.6% through 2032. The region leads due to established EBUS capacity, lung-cancer screening reimbursement, interventional pulmonology programs, and early adoption of robotic bronchoscopy. For example, Intuitive continues to expand Ion capabilities, while Johnson & Johnson is developing the MONARCH platform for peripheral lung-biopsy procedures.

 

Europe

Europe held an estimated 28% market share in 2025, equal to approximately USD 308 million, and is projected to expand at a CAGR of 6.1% through 2032. Demand combines conventional bronchoscopy, EBUS-guided cancer staging, and increasing clinical use of transbronchial cryobiopsy in selected ILD cases. For example, Germany-based ERBE supplies flexible single-use cryoprobes, while Boston Scientific markets its Acquire Pulmonary EBUS-FNB device in Europe for pulmonary tissue acquisition.

 

Asia-Pacific

Asia-Pacific represented an estimated 24% share in 2025, approximately USD 264 million, and is expected to record the fastest regional CAGR of 7.5% through 2032. The region combines a large lung-cancer burden with expanding tertiary hospitals and interventional pulmonary services. IARC data identify lung cancer as the leading cancer by cases across Asia. For example, Olympus has a large pulmonary endoscopy portfolio originating from Japan, while the TARGET robotic-bronchoscopy study included clinical sites in Hong Kong, reflecting increasing participation in advanced pulmonary biopsy programs.

 

Latin America

Latin America accounted for an estimated 5% market share in 2025, representing approximately USD 55 million, and is forecast to grow at a CAGR of 5.8% through 2032. Demand is concentrated in major urban hospitals and cancer centers where EBUS and specialist bronchoscopy capacity is available. Expansion of oncology diagnostics and private hospital investment can gradually increase use of disposable biopsy needles and forceps, particularly in larger healthcare markets.

 

Middle East & Africa

The Middle East & Africa represented an estimated 4% share in 2025, equivalent to approximately USD 44 million, and is projected to expand at a CAGR of 5.4% through 2032. Demand remains concentrated in tertiary and specialist hospitals, with adoption influenced by access to trained pulmonologists and advanced diagnostic infrastructure. Growth is expected to follow expansion of oncology services and bronchoscopy capacity in major metropolitan healthcare systems.

 

Competition Analysis

Competition in the Bronchial Biopsy Devices Market centers on pulmonary endoscopy portfolios, biopsy-tool compatibility, tissue acquisition, physician familiarity, recurring consumable sales, and reliability.

Olympus Corporation – Global Leader in Advanced Bronchoscopic Visualization & Biopsy Innovation

Olympus offers flexible and EBUS bronchoscopes, pulmonary biopsy forceps, and needle-based tissue-acquisition products. Its BF-MP190F supports multiple sampling tools for distal airway access. In January 2026, Olympus expanded the removal of all lots of its ViziShot 2 FLEX 19G EBUS-TBNA needle following reports involving component detachment or ejection, increasing the commercial importance of product reliability within the EBUS needle segment.

 

Boston Scientific – Precision EBUS-FNB Technology Powering Lung Cancer & Mediastinal Diagnostics

Boston Scientific competes through the Acquire Pulmonary EBUS Fine Needle Biopsy Device. The portfolio connects the company directly with lung-cancer diagnosis and staging, mediastinal lesions, suspected lymphoma, and sarcoidosis tissue sampling.

 

Medtronic – Expanding Peripheral Lung Biopsy Reach with Integrated Pulmonary Sampling Solutions

Medtronic provides Arcpoint pulmonary needles, GenCut core-biopsy devices, aspirating needles, and superDimension biopsy forceps. Its pulmonary tools target endobronchial lesions, peripheral nodules, and lung masses, providing exposure to expanding peripheral-biopsy procedures.

 

ERBE Elektromedizin – Cryobiopsy Pioneer Driving High-Yield Lung Tissue Acquisition Technologies

ERBE is differentiated through flexible single-use cryoprobes used for endobronchial, transbronchial, and peripheral pulmonary cryobiopsy. Its smaller-diameter probes also support biopsy approaches involving navigation catheters and small bronchoscopes.

The Bronchial Biopsy Devices Market is increasingly shaped by lung-cancer screening, incidental pulmonary-nodule follow-up, EBUS-guided sampling, peripheral lesion access, recurring disposable-device consumption, and expansion of interventional pulmonology. Lung cancer remains the largest application, hospitals remain the dominant purchasing group, needle-based biopsy devices show the strongest product growth, and Asia-Pacific presents the fastest regional expansion as diagnostic capacity broadens.

 

Bronchial Biopsy Devices Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.1 Billion
Revenue Forecast in 2032	USD 1.8 Billion
Overall Growth Rate	CAGR of 6.4% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Flexible Bronchoscopes, Needle-Based Biopsy Devices, Forceps
By Application	Lung Cancer Diagnosis, Chronic Obstructive Pulmonary Disease (COPD) Diagnosis, Asthma and Other Respiratory Conditions
By End User	Hospitals, Diagnostic Clinics, Research Institutions, Contract Research Organizations
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising lung cancer diagnosis and pulmonary nodule detection; expanding use of EBUS-guided and needle-based tissue sampling; growing adoption of robotic and navigation-assisted bronchoscopy; increasing demand for high-quality biopsy specimens for molecular profiling and biomarker testing
Customization Option	Available upon request